Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Cash & Equivalents (2016 - 2026)

Champions Oncology has reported Cash & Equivalents over the past 17 years, most recently at $7.1 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $7.1 million for Q1 2026, up 121.74% from a year ago — trailing twelve months through Jan 2026 was $7.1 million (up 121.74% YoY), and the annual figure for FY2025 was $9.8 million, up 273.76%.
  • Cash & Equivalents for Q1 2026 was $7.1 million at Champions Oncology, down from $8.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CSBR hit a ceiling of $10.8 million in Q4 2022 and a floor of $2.6 million in Q2 2024.
  • Median Cash & Equivalents over the past 5 years was $6.3 million (2023), compared with a mean of $6.2 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 49.93% in 2024 and later skyrocketed 273.76% in 2025.
  • Champions Oncology's Cash & Equivalents stood at $10.8 million in 2022, then crashed by 49.07% to $5.5 million in 2023, then tumbled by 49.93% to $2.8 million in 2024, then surged by 209.22% to $8.5 million in 2025, then dropped by 16.63% to $7.1 million in 2026.
  • The last three reported values for Cash & Equivalents were $7.1 million (Q1 2026), $8.5 million (Q4 2025), and $10.3 million (Q3 2025) per Business Quant data.